Citigroup resumed coverage on Apria with a new price target
$APR
Medical/Dental Instruments
Health Care
Citigroup resumed coverage of Apria with a rating of Buy and set a new price target of $39.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/11/2022 | $37.50 | Buy → Neutral | UBS |
| 1/10/2022 | $39.00 | Buy | Citigroup |
| 11/19/2021 | $39.00 | Buy | Citigroup |
| 11/8/2021 | $43.00 | Buy | Citigroup |
| 7/19/2021 | $32.00 → $29.00 | Buy → Neutral | Goldman Sachs |
| 6/30/2021 | $33.00 | Buy | Citigroup |
4 - Apria, Inc. (0001735803) (Issuer)
4 - Apria, Inc. (0001735803) (Issuer)
4 - Apria, Inc. (0001735803) (Issuer)
INDIANAPOLIS, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR), a leading provider of integrated home healthcare equipment and related services in the United States, announced today financial results for the fourth quarter and full year ended December 31, 2021. As previously announced, the Company will not be hosting a conference call to discuss its financial results. "We reported solid fourth quarter financial results and 2021 was a good year for Apria. Our team did an excellent job operating and executing at a high level while navigating the challenges from the COVID-19 pandemic, as well as a major product recall and supply chain constraints. Fourth
INDIANAPOLIS, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR), a leading provider of home medical equipment, supplies and related services in the United States, announced today that the waiting period has expired under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with its previously announced transaction with Owens & Minor, Inc. The closing of the transaction remains subject to approval by holders of a majority of the Company's outstanding common stock and other customary closing conditions. About Apria Apria is a leading provider of integrated home healthcare equipment and related services in the United States,
Highly Complementary Transaction Expands Patient Direct Offering Year-One Accretion Across Key Financial Metrics and Free Cash Flow Enhancement Creates a Leading Platform for Future Growth Owens & Minor, Inc. ("Owens & Minor") (NYSE:OMI) and Apria, Inc. ("Apria") (NASDAQ:APR) today announced that the companies have entered into a definitive agreement pursuant to which Owens & Minor will acquire Apria for $37.50 in cash per share of common stock, representing an equity value of approximately $1.45 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220110005291/en/ "I'm very excited about the acquisition of Apria, which wil
15-12B - Apria, Inc. (0001735803) (Filer)
25-NSE - Apria, Inc. (0001735803) (Subject)
S-8 POS - Apria, Inc. (0001735803) (Filer)
UBS downgraded Apria from Buy to Neutral and set a new price target of $37.50
Citigroup resumed coverage of Apria with a rating of Buy and set a new price target of $39.00
Citigroup resumed coverage of Apria with a rating of Buy and set a new price target of $39.00